See more : Arcimoto, Inc. (FUV) Income Statement Analysis – Financial Results
Complete financial analysis of Bionomics Limited (BNOEF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bionomics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DSP Group, Inc. (DSPG) Income Statement Analysis – Financial Results
- SolGold Plc (SLGGF) Income Statement Analysis – Financial Results
- Emirates Integrated Telecommunications Company PJSC (DU.AE) Income Statement Analysis – Financial Results
- Hempsana Holdings Ltd. (HMPS.CN) Income Statement Analysis – Financial Results
- Enbridge Inc (ENBGF) Income Statement Analysis – Financial Results
Bionomics Limited (BNOEF)
About Bionomics Limited
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 20.00K | 260.00K | 0.00 | 50.00K | 3.82M | 8.79M | 20.79M | 14.33M |
| Cost of Revenue | 434.45K | 13.06M | 11.05M | 4.32M | 4.02M | 8.52M | 18.69M | 18.62M | 18.45M |
| Gross Profit | -434.45K | -12.63M | -6.87M | -3.62M | -1.96M | -3.35M | -9.89M | 2.17M | -4.13M |
| Gross Profit Ratio | 0.00% | -2,919.26% | -164.21% | -520.89% | -94.76% | -64.71% | -112.49% | 10.44% | -28.81% |
| Research & Development | 9.42B | 19.61M | 16.00M | 5.76M | 5.83M | 8.98M | 18.69M | 18.62M | 18.45M |
| General & Administrative | 8.47B | 5.75M | 5.11M | 3.28M | 2.53M | 4.68M | 6.86M | 4.40M | 5.61M |
| Selling & Marketing | 0.00 | 146.76K | 181.19K | 954.12K | 814.69K | 851.00K | 1.05M | 1.99M | 2.26M |
| SG&A | 8.47B | 8.86M | 7.66M | 5.65M | 4.85M | 9.35M | 7.91M | 6.40M | 7.87M |
| Other Expenses | 0.00 | 0.00 | 6.67K | 203.01K | 200.28K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.89B | 32.00M | 21.61M | 11.92M | 9.06M | 19.18M | 8.44M | 6.37M | 8.28M |
| Cost & Expenses | 17.89B | 22.09M | 19.32M | 6.29M | 5.01M | 10.99M | 27.12M | 24.99M | 26.73M |
| Interest Income | 0.00 | 480.00K | 10.00K | 10.00K | 60.00K | 280.00K | 1.10M | 589.10K | 497.43K |
| Interest Expense | 0.00 | 20.00K | 30.00K | 1.17M | 1.79M | 2.36M | 1.51M | 1.37M | 1.41M |
| Depreciation & Amortization | 434.45K | 778.25K | 804.54K | 1.27M | 1.64M | 1.22M | 1.29M | 1.31M | 1.41M |
| EBITDA | -9.84M | -20.90M | -11.51M | -4.97M | -4.19M | -7.87M | -16.57M | -2.88M | -10.55M |
| EBITDA Ratio | 0.00% | -4,130.83% | -275.36% | -1,006.21% | -202.73% | -152.27% | -188.39% | -13.88% | -73.65% |
| Operating Income | -17.89B | -31.97M | -21.34M | -11.92M | -9.01M | -15.36M | -17.80M | -4.22M | -11.99M |
| Operating Income Ratio | 0.00% | -4,282.63% | -290.62% | -1,107.29% | -250.19% | -171.73% | -202.42% | -20.32% | -83.72% |
| Total Other Income/Expenses | 17.88B | -2.99M | -3.01M | 1.04M | 4.85M | 7.94M | -1.63M | -562.01K | -911.70K |
| Income Before Tax | -10.27M | -32.05M | -21.95M | -8.88M | -6.03M | -9.91M | -19.43M | -4.79M | -12.91M |
| Income Before Tax Ratio | 0.00% | -4,934.35% | -362.51% | -957.30% | -201.41% | -143.60% | -220.90% | -23.02% | -90.09% |
| Income Tax Expense | -87.32M | -210.00K | -190.00K | -190.00K | -210.00K | -240.00K | 859.40K | 401.64K | 545.09K |
| Net Income | -15.49B | -31.85M | -21.76M | -8.70M | -7.12M | -9.67M | -18.57M | -5.19M | -12.36M |
| Net Income Ratio | 0.00% | -4,902.51% | -359.34% | -937.11% | -194.47% | -141.25% | -211.13% | -24.95% | -86.28% |
| EPS | -1.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | -0.07 | -0.02 | -0.05 |
| EPS Diluted | -1.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | -0.07 | -0.02 | -0.05 |
| Weighted Avg Shares Out | 9.99M | 1.47B | 1.35B | 779.88M | 544.83M | 521.26M | 267.94M | 267.42M | 254.03M |
| Weighted Avg Shares Out (Dil) | 9.99M | 1.47B | 1.35B | 779.88M | 544.83M | 521.26M | 267.94M | 267.42M | 256.28M |
Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders...
Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States
ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with...
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement
ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with...
Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program
ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders...
Bionomics to Present at the ThinkEquity Conference
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders...
Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with...
Bionomics Limited announces intention to re-domicile to the United States
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system...
Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatment
Shares of Bionomics Limited rocketed 387% after phase IIb trial results showed its lead asset had the potential to become a best-in-class treatment for post-traumatic stress disorder (PTSD). Researchers found that the drug, BNC210, significantly reduced the severity of PTSD symptoms...
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial
Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data...
Bionomics Announces Plans to Conduct U.S. Initial Public Offering
ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in...
Source: https://incomestatements.info
Category: Stock Reports